2019 should represent a turning point for Sorrento Therapeutics, H.C. Wainwright analyst Raghuram Selvaraju tells investors in a research note. The analyst believes the company is in position to report "multiple value-driving clinical data catalysts" over the course of 2019, both with its pain management portfolio and its cancer immunotherapy candidates. He thinks the interest in anti-CD38 CAR-T approaches has only increased following the recently concluded American Society for Hematology annual meeting. Further, Sorrento's recent financing transactions "provide a pathway to sustainability," adds Selvaraju. He reiterates a Buy rating on the shares with a $40 price target.